Akero Therapeutics, Inc. (NASDAQ:AKRO) Insider Sells $251,261.53 in Stock

Akero Therapeutics, Inc. (NASDAQ:AKRO) insider Catriona Yale sold 9,061 shares of the business’s stock in a transaction dated Friday, November 15th. The shares were sold at an average price of $27.73, for a total value of $251,261.53. Following the completion of the transaction, the insider now directly owns 74,158 shares of the company’s stock, valued at approximately $2,056,401.34. This trade represents a 10.89 % decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through the SEC website.

Catriona Yale also recently made the following trade(s):

• On Friday, November 1st, Catriona Yale sold 15,485 shares of Akero Therapeutics stock. The shares were sold at an average price of $32.62, for a total transaction of $505,120.70.
• On Wednesday, October 30th, Catriona Yale sold 4,515 shares of Akero Therapeutics stock. The stock was sold at an average price of $32.53, for a total transaction of $146,872.95.
• On Monday, October 14th, Catriona Yale sold 6,136 shares of Akero Therapeutics stock. The shares were sold at an average price of $30.03, for a total transaction of $184,264.08.
• On Friday, September 20th, Catriona Yale sold 5,500 shares of Akero Therapeutics stock. The shares were sold at an average price of $27.65, for a total value of $152,075.00.
• On Wednesday, September 18th, Catriona Yale sold 3,871 shares of Akero Therapeutics stock. The stock was sold at an average price of $27.56, for a total value of $106,684.76.
• On Monday, September 16th, Catriona Yale sold 2,485 shares of Akero Therapeutics stock. The shares were sold at an average price of $27.52, for a total value of $68,387.20.
• On Tuesday, September 10th, Catriona Yale sold 637 shares of Akero Therapeutics stock. The stock was sold at an average price of $26.18, for a total value of $16,676.66.
• On Friday, August 23rd, Catriona Yale sold 8,851 shares of Akero Therapeutics stock. The shares were sold at an average price of $27.53, for a total transaction of $243,668.03.
• On Monday, August 26th, Catriona Yale sold 5,200 shares of Akero Therapeutics stock. The stock was sold at an average price of $27.51, for a total transaction of $143,052.00.

Akero Therapeutics Trading Up 5.0 %

Shares of Akero Therapeutics stock traded up $1.47 during trading on Tuesday, hitting $31.03. The company’s stock had a trading volume of 799,605 shares, compared to its average volume of 868,442. The stock has a market cap of $2.17 billion, a price-to-earnings ratio of -8.27 and a beta of -0.26. The company has a debt-to-equity ratio of 0.05, a current ratio of 17.25 and a quick ratio of 17.25. Akero Therapeutics, Inc. has a 52 week low of $15.32 and a 52 week high of $37.00. The stock has a 50-day moving average price of $29.63 and a two-hundred day moving average price of $25.81.

Akero Therapeutics (NASDAQ:AKRO) last issued its quarterly earnings results on Friday, November 8th. The company reported ($1.05) earnings per share for the quarter, missing the consensus estimate of ($0.90) by ($0.15). Equities research analysts anticipate that Akero Therapeutics, Inc. will post -3.96 EPS for the current fiscal year.

Analysts Set New Price Targets

Several research analysts have recently issued reports on the stock. HC Wainwright reiterated a “buy” rating and set a $50.00 price target on shares of Akero Therapeutics in a report on Monday. Citigroup started coverage on Akero Therapeutics in a report on Monday. They issued a “buy” rating and a $65.00 target price for the company. One equities research analyst has rated the stock with a hold rating and seven have given a buy rating to the stock. According to MarketBeat, Akero Therapeutics currently has a consensus rating of “Moderate Buy” and a consensus price target of $46.83.

Institutional Trading of Akero Therapeutics

A number of institutional investors and hedge funds have recently added to or reduced their stakes in the company. Mirae Asset Global Investments Co. Ltd. lifted its position in shares of Akero Therapeutics by 21.6% in the 3rd quarter. Mirae Asset Global Investments Co. Ltd. now owns 2,511 shares of the company’s stock worth $71,000 after purchasing an additional 446 shares during the period. Ameritas Investment Partners Inc. lifted its holdings in Akero Therapeutics by 20.0% in the first quarter. Ameritas Investment Partners Inc. now owns 6,175 shares of the company’s stock valued at $156,000 after buying an additional 1,030 shares during the period. Russell Investments Group Ltd. boosted its position in Akero Therapeutics by 2,366.0% during the first quarter. Russell Investments Group Ltd. now owns 1,233 shares of the company’s stock valued at $31,000 after acquiring an additional 1,183 shares during the last quarter. Y Intercept Hong Kong Ltd grew its holdings in Akero Therapeutics by 13.8% during the 3rd quarter. Y Intercept Hong Kong Ltd now owns 16,916 shares of the company’s stock worth $485,000 after acquiring an additional 2,049 shares during the period. Finally, Handelsbanken Fonder AB raised its position in shares of Akero Therapeutics by 12.4% in the 3rd quarter. Handelsbanken Fonder AB now owns 20,000 shares of the company’s stock worth $574,000 after acquiring an additional 2,200 shares in the last quarter.

Akero Therapeutics Company Profile

Akero Therapeutics, Inc, together with its subsidiary, engages in the development of treatments for patients with serious metabolic diseases in the United States. The company's lead product candidate is efruxifermin (EFX), which is in Phase 3 clinical trials that protects against cellular stress and regulates the metabolism of lipids, carbohydrates, and proteins throughout the body for the treatment of biopsy-confirmed metabolic dysfunction-associated steatohepatitis (MASH) patients.